Entera Bio (ENTX) Capital Expenditures (2021 - 2026)
Entera Bio's (ENTX) quarterly Capital Expenditures came in at $27000.0 in Q4 2025, up 800.0% YoY from $3000.0 in Q4 2024, and down 37.21% on a QoQ basis from $43000.0 in Q3 2025.
Entera Bio (ENTX) Capital Expenditures (2021 - 2026) Analysis & Trends
Entera Bio (ENTX) has 5 years of Capital Expenditures data on file, last reported at $27000.0 in Q4 2025.
- Quarterly Capital Expenditures rose 800.0% year-over-year to $27000.0 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $99000.0 (up 800.0% YoY) and the FY2025 annual result came in at $107000.0, up 3466.67% from the prior year.
- Capital Expenditures fell to $27000.0 in Q4 2025, from $43000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $43000.0 in Q3 2025 to a low of $1000.0 in Q2 2023.
- A 5-year average of $13642.9 and a median of $9000.0 in 2021 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2023 — Capital Expenditures plunged 94.74% — and 2025, when it surged 800.0%.
- Tracing ENTX's Capital Expenditures over 5 years: stood at $10000.0 in 2021, then slumped by 70.0% to $3000.0 in 2022, then soared by 66.67% to $5000.0 in 2023, then sank by 40.0% to $3000.0 in 2024, then surged by 800.0% to $27000.0 in 2025.
- The last three Capital Expenditures figures came in at $27000.0 (Q4 2025), $43000.0 (Q3 2025), and $29000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 251.02 Mn |
| 10 | Entera Bio | 161.44 Mn | 150.13 Mn | - | 3,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3,000.00 |
| Jun 30, 2026 | 3,000.00 |
| Dec 31, 2025 | 27,000.00 |
| Dec 31, 2025 | 27,000.00 |
| Sep 30, 2025 | 43,000.00 |
| Sep 30, 2025 | 43,000.00 |
| Jun 30, 2025 | 29,000.00 |
| Jun 30, 2025 | 29,000.00 |
| Mar 31, 2025 | 8,000.00 |
| Mar 31, 2025 | 8,000.00 |
| Dec 31, 2024 | 3,000.00 |
| Dec 31, 2024 | 3,000.00 |
| Dec 31, 2023 | 5,000.00 |
| Dec 31, 2023 | 5,000.00 |
| Jun 30, 2023 | 1,000.00 |
| Jun 30, 2023 | 1,000.00 |
| Mar 31, 2023 | 11,000.00 |
| Mar 31, 2023 | 11,000.00 |
| Dec 31, 2022 | 3,000.00 |
| Dec 31, 2022 | 3,000.00 |